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Preventing psychosis in patients at clinical high risk may be a promising avenue for pre-
emptively ameliorating outcomes of the most severe psychiatric disorder. However, 
information on how each preventive intervention fares against other currently available 
treatment options remains unavailable. The aim of the current study was to quantify the 
consistency and magnitude of effects of specific preventive interventions for psychosis, 
comparing different treatments in a network meta-analysis. PsycINFO, Web of Science, 
Cochrane Central Register of Controlled Trials, and unpublished/grey literature were 
searched up to July 18, 2017, to identify randomized controlled trials conducted in 
individuals at clinical high risk for psychosis, comparing different types of intervention and 
reporting transition to psychosis. Two reviewers independently extracted data. Data were 
synthesized using network meta-analyses. The primary outcome was transition to psychosis 
at different time points and the secondary outcome was treatment acceptability (dropout due 
to any cause). Effect sizes were reported as odds ratios and 95% CIs. Sixteen studies 
(2,035 patients, 56% male, mean age 20 years) reported on risk of transition. The 
treatments tested were needs-based interventions (NBI); omega-3 + NBI; ziprasidone + NBI; 
olanzapine + NBI; aripiprazole + NBI; integrated psychological interventions; family therapy 
+ NBI; D-serine + NBI; cognitive behavioural therapy, French & Morrison protocol (CBT-F) + 
NBI; CBT-F + risperidone + NBI; and cognitive behavioural therapy, van der Gaag protocol 
(CBT-V) + CBT-F + NBI. The network meta-analysis showed no evidence of significantly 
superior efficacy of any one intervention over the others at 6 and 12 months (insufficient 
data were available after 12 months). Similarly, there was no evidence for intervention 
differences in acceptability at either time point. Tests for inconsistency were non-significant 
and sensitivity analyses controlling for different clustering of interventions and biases did not 
materially affect the interpretation of the results. In summary, this study indicates that, to 
date, there is no evidence that any specific intervention is particularly effective over the 
others in preventing transition to psychosis. Further experimental research is needed.  
 
Key words: Psychosis, risk, prevention, needs-based interventions, cognitive behavioural 
therapy, antipsychotics, omega-3, integrated psychological interventions, family therapy, 
network meta-analysis, guidelines 
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Individuals at clinical high risk for psychosis (CHR-P)1 present with attenuated psychotic 
symptoms, impairments of social, emotional and cognitive functioning2, and help-seeking 
behaviour3. They have around 20% risk of developing psychosis (but not any other non-
psychotic disorder4,5) over a two-year period6.  
Primary indicated prevention in CHR-P individuals has the unique potential to alter the 
course of the disorder7 and improve clinical outcomes8. Current international guidelines – 
such as those of the National Institute for Health and Care Excellence (NICE) and the 
European Psychiatric Association (EPA) – recommend that CHR-P individuals be primarily 
offered cognitive behavioural therapy (CBT) with or without family interventions9,10. However, 
while prophylactic treatment with antipsychotics is altogether prohibited by NICE guidelines9, 
the EPA allows its use in the case of severe and progressive symptomatology10.  
The evidence supporting these partially conflicting recommendations is relatively 
unclear11, despite several pairwise meta-analyses having been published to date10,12-18. For 
example, earlier meta-analyses concluded that no reliable recommendations with respect to 
specific interventions could be made, because studies were too heterogeneous12, with 
comparable efficacy across different treatments16 or no effects at all17. The most recent 
meta-analysis concluded that both CBT and antipsychotics are effective13. The other meta-
analyses were affected by mistakes19 or methodological limitations, such as the use of 
overall effect sizes computed across heterogeneous interventions of questionable clinical 
interpretability10,12,18, inclusion of patients not assessed with standard CHR-P instruments 
(e.g., with schizotypal disorders20)12,13,15,18, inclusion of non-randomized and uncontrolled 
trials10, pooling of time-dependent outcomes21 in the same group (e.g., 6 and 12 months18) 
or no time stratification at all13, or poor meta-analytical approaches13. Meta-analyses have 
acquired a major influence on clinical practice and guidelines22, so they can be particularly 
harmful if they are of suboptimal quality.  
Another problem is that the included trials involved a variety of specific interventions12, 
which were inconsistently clustered in pairwise comparisons. For example, although CBT is 
an umbrella term for a plethora of heterogeneous strategies23, different CBT protocols have 
been lumped together, and the specific efficacy of each defining element or specific protocol 
remains unclear24.  
The objective of this network meta-analysis (NMA) was to summarize the available 
evidence about the specific efficacy of different preventive interventions in CHR-P individuals. 
NMA offers additional benefits over standard pairwise analyses in that the comparative 
efficacy of specific interventions can be estimated and ranked, even when two treatments 
have never been compared directly head-to-head25. Furthermore, since NMA can improve 
the precision of estimates by allowing integration of both direct and indirect treatment effect 
estimates26, it is recommended over pairwise meta-analyses by the World Health 
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Organization as a basis for clinical guidelines27. Therefore, NMA should be considered the 
highest level of evidence in CHR-P treatment guidelines28.  
 
 
METHODS  
 
The protocol for this study was registered on PROSPERO (CRD42017069550). The 
study was conducted in accordance with the PRISMA statement29. 
 
Interventions included 
 
We included all randomized controlled trials (RCTs) of pharmacological and/or non-
pharmacological interventions for CHR-P individuals. We were a priori interested in the 
following non-pharmacological interventions: CBT (various protocols), psychoeducation, 
family therapy, supportive counselling, needs-based interventions (NBI), and integrated 
psychological therapies. We were also interested in the following pharmacological 
interventions: antipsychotics (olanzapine, risperidone, ziprasidone, aripiprazole) and 
novel/experimental pharmacotherapies (omega-3 fatty acids and D-serine). As indicated in 
the protocol, additional interventions emerging from the literature search were also 
considered (e.g., glycine and cognitive remediation).  
The definition of the exact types of interventions is essential to reduce heterogeneity and 
produce robust informative results of direct clinical significance. As such, we first took each 
trial and carefully identified the treatment components that were characterizing each specific 
intervention, as detailed below.  
 
Needs-based interventions (NBI) 
 
Since CHR-P patients recruited in clinical trials are help-seeking adolescents and young 
adults accessing clinical services, randomizing them to no treatment is not considered a 
reasonable or ethical option30. Defining “treatment as usual” in these samples is also 
challenging, because treatment is not standardized and largely depends on local service 
configurations and the availability of specific resources or competences.  
We therefore used the most established and original definition of NBI employed by the 
founders of the CHR-P paradigm, which focuses on the presenting symptoms and problems 
already manifest31. In accordance with this definition32, NBI may include any of the following 
components: a) supportive psychotherapy primarily focusing on pertinent issues such as 
social relationships and vocational or family problems; b) case management, providing 
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psychosocial assistance with accommodation, education or employment; c) brief family 
psychoeducation and support; d) medications other than antipsychotics; and e) clinical 
monitoring and crisis management31,33. 
  
Cognitive behavioural therapy, French & Morrison protocol (CBT-F) 
 
The CBT-F protocol34 is based on the principles developed by Beck35. The intervention 
is formulation-driven, problem-focused and time-limited, with manualized strategies selected 
on the basis of the patient’s prioritized problem. The key components include building 
engagement, collaborative goal-setting and formulation, normalizing experiences, evaluating 
appraisals and core beliefs, and behavioural experiments34,36. 
 
Cognitive behavioural therapy, van der Gaag protocol (CBT-V) 
 
The protocol developed by van der Gaag et al37 essentially includes the French & 
Morrison protocol34, but with two additional components. These comprise psychoeducation 
about dopamine system supersensitivity and training/behavioural experiments on cognitive 
biases that may contribute to paranoia38. Further behavioural goals include sustaining school 
and work attendance, enhancing social relationships, and reducing cannabis use37.  
 
Integrated psychological interventions, Bechdolf protocol (IPI) 
 
The protocol developed by Bechdolf et al39 contains a number of components, including 
individual CBT-F34, manualized group social skills training, computerized cognitive 
remediation to address thought and perception deficits, and manualized psychoeducational 
multi-family group sessions39,40. 
 
Family-focused therapy, Miklowitz protocol (FFT) 
 
A family-focused therapy (FFT) protocol, initially designed for those with or at risk of 
bipolar disorder, was adapted by Miklowitz et al41 for the CHR-P population. The key 
components include psychoeducation and development of a prevention plan with the patient 
and family, sessions where the patient and family practice skills for better communication, 
and sessions focusing on enhancing problem solving skills41. 
 
 
 
 6 
Psychopharmacological interventions 
 
Pharmacological interventions included currently licensed medications, novel or 
experimental pharmacotherapies, and nutritional supplements.  
 
Placebo 
 
The placebo designation was reserved for placebo pills administered as 
pharmacological control conditions. Placebos were designed to match the active drug 
intervention in appearance but without the pharmacological compound of interest. 
 
Nodes for the network meta-analysis 
 
The specific interventions listed above were pooled into “nodes” for the network meta-
analysis. Nodes were defined by the linear combination of any of the above specific 
interventions. Each individual pharmacological treatment was assigned to its own node. As 
indicated in the protocol, different dosages of the same drug/molecule were classed under 
the same node. Placebo was initially considered as a separate node from NBI. However, in 
line with the protocol, sensitivity analyses investigated the effect of alternate clustering of 
nodes (see statistical analysis).  
 
Search strategy and selection criteria 
 
We performed a multi-step literature search using the following keywords: (risk OR 
prodromal OR prodrom* OR ultra high risk OR clinical high risk OR high risk OR genetic high 
risk OR at risk mental state OR risk of progression OR progression to first-episode OR 
prodromally symptomatic OR basic symptoms) AND (psychosis) AND (RCT OR randomized 
controlled trial OR placebo controlled trial OR trial).  
First, systematic searches were conducted in the Web of Science (which includes Web 
of Science Core Collection, BIOSIS Citation Index, KCI - Korean Journal Database, 
MEDLINE, Russian Science Citation Index and SciELO Citation Index), the Cochrane 
Central Register of Controlled Trials, and Ovid/PsychINFO databases, until July 18, 2017, 
with no restrictions on language or publication date.  
Second, we used Scopus/Web of Science to search reference lists of retrieved articles 
and previously conducted systematic reviews and meta-analyses. We manually searched for 
published and unpublished data in relevant conference proceedings, trial registries and 
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drug-approval agencies. In addition, we contacted study authors for supplemental data and 
searched the OpenGrey database for grey literature.  
Abstracts identified by this process were then screened, and full-text articles were 
retrieved for further inspection against the inclusion and exclusion criteria (as detailed a 
priori in the protocol). The literature search, study selection and data extraction were 
conducted by two authors (CD, UP) independently. During all stages, in the case of 
disagreement, consensus was reached through discussion with a third author (PFP).  
Studies were eligible for inclusion when the following criteria were fulfilled: a) original 
articles, abstracts or pilot studies; b) RCTs (including cluster randomized trials, but excluding 
cross-over studies); c) designed as blinded (either single- or double-blind); d) conducted in 
CHR-P individuals as established by validated assessments, i.e. Comprehensive 
Assessment of At-Risk Mental States (CAARMS)42, Structured Interview for Psychosis-risk 
Syndromes (SIPS)43,44, Positive and Negative Syndrome Scale (PANSS)45, Brief Psychiatric 
Rating Scale (BPRS)46, or Early Recognition Inventory (ERIraos)47; e) comparing specific 
preventive interventions as defined above; and f) sample size >1048.  
The exclusion criteria were: a) reviews/non-original data; b) studies lacking at least two 
compared groups; c) studies of first-episode psychosis or other non-CHR-P groups; d) lack 
of data needed for meta-analytical computation of the primary (transition) outcome (authors 
were contacted and asked to provide summary data); e) lack of proper randomization (quasi-
randomization, observational naturalistic studies); f) sample size < 10; and g) articles 
presenting overlapping, redundant data (for a particular outcome at the same time point). 
Specifically, in the case of overlapping samples, we used the largest one. Studies that were 
designed as blinded but could not maintain blinding during follow-up (e.g., for psychological 
interventions) were not excluded.  
 
Outcome measures and data extraction 
 
The primary outcome was transition to psychosis. Due to the variable effect of time on 
transition risk6,21, we stratified outcomes and analyses into 6 and 12 month follow-up time 
points. Sample sizes were based on the numbers randomized to each arm, to prevent 
artificial inflation of transition risk6,49.  Participants who dropped out of individual studies after 
randomization were classified as non-transitions6,10,14,50.  
Where studies did not report sufficient data to extract the primary outcome, we contacted 
the relevant authors. In the case of non-response or where studies presented data 
graphically, numerical data were digitally extracted from the Kaplan-Maier plots using a 
previously validated procedure51,52, as defined in the protocol.  
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The secondary outcome was the acceptability of interventions (discontinuation due to 
any cause), indexed as the number of participants who dropped out of each arm for any 
reason following randomization, over the number randomized53-55.  
In addition, we extracted the following information for each study: first author and year of 
publication, country, types of outcomes, intervention and control descriptions, study design, 
quality assessment (see below), intervention period and follow-up duration, study arm details 
(sample size, mean age, percent male), source of patients/sampling procedure, and 
diagnostic tools used for CHR-P diagnosis and determining transition to psychosis. 
 
Quality of the evidence  
 
Risk of bias 
 
The Cochrane Risk of Bias tool56 was used to assess and classify the risk of bias in 
each of the included studies, as per criteria defined a priori. A judgement was made about 
whether each study had a high, low or unclear risk of bias in each of the following six 
domains: random sequence generation, allocation concealment, blinding of participants and 
study personnel, blinding of outcome assessments, incomplete outcome data, and selective 
outcome reporting.  
The overall risk of bias was classified as low if none of the above domains was rated as 
high risk and three or less were rated as unclear risk. It was classified as moderate if one 
domain was rated as high risk, or none rated as high risk but four or more rated as unclear 
risk. All other studies were classified as having a high risk of bias57.  
To represent the quality of evidence associated with comparisons in the network meta-
analysis, we used coloured edges in the network plots, as recommended58. 
 
GRADE 
 
We assessed the certainty of evidence contributing to network estimates of the primary 
outcome using the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) framework59. The GRADE method characterizes the quality of a body of evidence 
on the basis of six factors: study limitations, imprecision, heterogeneity, inconsistency, 
indirectness, and publication bias59.  
We tabulated the findings for the above six factors to aid in the decision-making process 
for the downgrading of evidence. If one of the factors was present for a comparison, then the 
overall confidence rating for that comparison was considered for downgrading by one or two 
levels (as appropriate). Each comparison started as high quality/confidence (as based on 
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RCTs), and was downgraded to moderate, low or very low, depending on the presence, 
severity and potential impact of the aforementioned factors. These represented the final 
judgements about the certainty of the evidence59,60. 
 
Statistical analysis 
 
Frequentist NMAs were conducted for transition and acceptability outcomes using the 
network package in STATA (version SE 14.2; StataCorp). First, a network plot was 
constructed for each outcome61 to ensure that nodes of the network were sufficiently 
connected58. We then performed a NMA assuming consistency and a common 
heterogeneity across all comparisons in the network. This allowed us to derive a single 
summary treatment effect (odds ratio, OR) for every possible pairwise comparison of 
treatments, which takes account of all evidence from the network of trials, including both 
direct and indirect comparisons. Correlations in effect sizes induced by multi-arm trials62 
were accounted for58,63. The resulting relative ORs with 95% confidence intervals (CIs) for 
each pair of treatments were reported in league tables64.  
The interventions were then ranked by the surface under the cumulative ranking curve 
(SUCRA), which accounts for the location as well as the variance of all relative treatment 
effects65. SUCRA is a numeric presentation of the overall ranking and provides a single 
number (from 0 to 100%) associated with each intervention66. The higher the SUCRA value, 
and the closer to 100%, the higher the likelihood that an intervention is in the top rank, and 
vice versa66.  Cluster ranking methods58,65 – using both transition and acceptability SUCRA 
values – were used to order the treatments in league tables, in line with recent guidance 
which requires interpretation of SUCRA only in the context of NMA uncertainty, rather than 
at face value66. Statistical significance was set at p<0.05. 
We assessed the assumption of consistency by calculating, for each closed loop, an 
inconsistency factor (differences between direct and indirect evidence) along with 95% CIs 
and associated p values. We plotted the results graphically as the ratio of odds ratios 
(RORs) and 95% CIs for each loop64. Inconsistency was defined as disagreement between 
direct and indirect evidence, with 95% CIs for RORs excluding 1.  
Given the low power of the loop-specific approach and its focus on local inconsistency 
(between direct and indirect evidence), we also tested a full design-by-treatment model62 for 
the primary outcome to evaluate inconsistency more globally, including between trials with 
different designs (e.g., two-arm vs. multi-arm). A NMA under the inconsistency model was 
applied and a χ2 test was used to infer about the statistical significance of all possible 
inconsistencies in the networks67. 
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The transitivity assumption was examined by assessing the distributions of potential 
effect modifiers for every comparison in the network, including percentage of males68, age69, 
percentage exposed to antipsychotic medications at baseline70, type of blinding and 
publication year6. The presence of small-study effects was assessed by visual inspection of 
comparison-adjusted funnel plots59.  
To evaluate the impact of study quality and our data analysis procedures, we conducted 
sensitivity analyses for the primary outcome restricted to: a) studies with a low risk of bias for 
the blinding of outcome assessments; b) studies whose data were not digitally extracted 
(e.g., from Kaplan-Meier plots); and c) published data only. We also repeated the analyses 
after applying alternate clustering of the following nodes: a) pooling NBI and placebo; b) 
pooling different CBT protocols; c) pooling different types of antipsychotic molecules, and d) 
separating the different NBI components (i.e., supportive therapy vs. clinical monitoring vs. 
other). Finally, network meta-regressions were planned in the case of substantial 
heterogeneity and at least ten studies71 to test the impact of different CHR-P diagnostic 
instruments/criteria. 
 
 
RESULTS  
 
Characteristics of the included studies 
 
1,556 references were found in the literature search, most of which were not reporting 
RCTs in CHR-P individuals; 49 were fully screened for the inclusion and exclusion criteria, 
resulting in a final sample of 16 studies (Figure 1). There were only five, four, two and three 
studies reporting data for 18, 24, 36 and >36 month time points, respectively, and therefore 
all results reported hereafter are for 6 and 12 months only.  
The 16 studies used in the analyses of the primary outcome contributed data on 2,035 
patients, with a mean age of 20.2±2.9 years, and 56% were male (Table 1). The mean 
sample size was 127 (range 44-304). Six studies were conducted in North America, six in 
Europe, three in Australia and one was multi-national. Two studies were three-arm and the 
rest were two-arm trials. Two studies had a treatment duration of <6 months, ten of 6 
months, and four of 12 months. Of the 14 studies with available information on 
sponsorship/funding, three31,75,81,82 acknowledged pharmaceutical company grants. The 
CAARMS and the SIPS were the most common CHR-P diagnostic instruments44 (six and 
seven studies, respectively).  
For the 6-month analysis of the primary outcome, these 16 studies provided data on 20 
direct comparisons between 11 different treatment nodes (Figure 2). Three studies provided 
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follow-up data only for the 6-month analysis, and therefore the 12-month analysis consisted 
of 13 studies (N=1,811), providing data on 17 direct comparisons between 8 different 
treatment nodes (Figure 2). The network plots for the acceptability outcome were the same 
at 12 months and similar at 6 months (integrated psychological interventions was missing).  
 
Primary outcome: transition 
 
Results of the NMA showed a lack of evidence for clearly superior efficacy of specific 
treatments in preventing transition, with no significant effects of any one intervention over 
any others at 6 or 12 month time points (Tables 2 and 3).  
Using NBI as a comparator, the OR and 95% CI for each treatment (all OR<1 favor the 
given treatment) at 6 months were: 0.06 (0.00-1.90) for integrated psychological 
interventions; 0.17 (0.01-2.69) for family therapy + NBI; 0.22 (0.02-2.17) for CBT-F + CBT-V 
+ NBI; 0.29 (0.03-2.57) for olanzapine + NBI; 0.21 (0.04-1.08) for CBT-F + risperidone + 
NBI; 0.52 (0.03-10.72) for ziprasidone + NBI; 0.56 (0.03-11.51) for D-serine + NBI; 0.64 
(0.15-2.68) for omega-3 + NBI; 0.73 (0.27-2.01) for CBT-F + NBI; and 0.94 (0.15-5.73) for 
aripiprazole + NBI.  
At 12 months, ORs against the NBI comparator were: 0.04 (0.00-1.06) for integrated 
psychological interventions; 0.15 (0.02-1.25) for olanzapine + NBI; 0.21 (0.03-1.60)  for CBT-
F + CBT-V + NBI; 0.43 (0.11-1.68) for CBT-F + risperidone + NBI; 0.58 (0.23-1.47) for CBT-
F + NBI; 0.64 (0.18-2.26) for omega-3 + NBI; and 1.39 (0.26-7.28) for aripiprazole + NBI.  
While almost all the interventions at both time points had estimates favoring them over 
NBI, the differences were not beyond chance, and the 95% CIs for the NMA estimates were 
often very large, indicating substantial imprecision. The cluster ranking (based on SUCRA 
values for transition and acceptability) at 6 and 12 months are illustrated by the ordering of 
treatments in Tables 2 and 3.  
No statistically significant inconsistency was evident at any time point, with 95% CIs for 
all RORs compatible with zero inconsistency (ROR=1). However, only two loops were 
available. Using the design-by-treatment interaction test62, we found no evidence for 
significant inconsistency for 6 month (p=0.90) and 12 month (p=0.93) networks. 
Only two studies had an overall low risk of bias33,79; five had unclear risk72-76, and nine 
had high risk30,31,36,37,39,41,77,78,81. The edges (lines) in Figure 2 reflect the Cochrane risk of 
bias for the blinding of outcome assessments, estimated as the level of bias in the majority 
of trials and weighted according to the number of studies in each comparison58. The GRADE 
assessment highlighted low or very low confidence in almost all estimates, primarily due to 
study limitations (high risks of bias) and imprecision. 
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The numbers of studies remaining (at 6 and 12 months, respectively) after exclusion of 
those with a high or unclear risk of bias for the blinding of outcome assessments were 10 
and 8; after exclusion of those whose data were extracted by digitizing Kaplan-Meier plots 
were 13 and 12; after exclusion of unpublished studies were 13 and 11. The NMA model 
was refitted accordingly and no differences in conclusions were observed for any OR at any 
time point.  
Repeating the analyses treating NBI + placebo as a separate node to NBI, or separating 
the different NBI components, had no effect on the NMA estimates and therefore we used 
the pooled NBI + placebo in the main analysis (Tables 1-3, Figure 2). Similarly, pooling 
together different CBT protocols or different antipsychotic molecules in the same node 
produced no significant results. There were not enough studies to allow robust meta-
regression analyses on the type of CHR-P instruments. Visual inspection of funnel plots 
revealed no substantive evidence of small-study effects.  
 
Secondary outcome: acceptability 
 
Acceptability data were available for 14 of 16 studies at 6 months (N=1,848), and 12 of 
13 studies at 12 months (N=1,752). There were no significant differences in acceptability 
between any treatment comparisons at 6 or 12 months (Tables 2 and 3). The SUCRA 
cluster ranking (for transition and acceptability) is illustrated in those tables. 
 
 
DISCUSSION  
 
This is the first network meta-analysis exploring the efficacy of specific interventions for 
the prevention of psychosis in CHR-P individuals. Adopting strict inclusion criteria, a total of 
16 RCTs, with 2,035 patients, were included in the analyses. There were not enough studies 
to analyze data with a NMA approach beyond 6 and 12 month follow-ups. Two networks 
were established at 6 and 12 months, including 11 and 8 nodes, respectively. Network meta-
analyses showed no clear evidence of superior efficacy for any specific intervention at any 
time point. The results were not affected by biases, inconsistency or small-study effects.  
The main finding of the current study is that there is a lack of evidence to favor specific 
effective interventions to prevent psychosis in CHR-P individuals. Our analyses were based 
on a detailed protocol, which defined the exact type of interventions and nodes a priori. This 
was done with the aim of providing robust informative results of direct clinical significance. 
For example, deconstructing the efficacy of different types of CBT that are based on different 
protocols83 seems necessary to inform accurate and evidence-based clinical guidelines for 
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patients, clinicians and policy makers. Our NMA comparing the different CBT protocols is 
also timely, since authors have recently claimed that the “black box” of CBT should be 
unpacked into its specific therapeutic components23,24,84-86.  
In a similar fashion, our NMA represents the first attempt at deconstructing – through 
sensitivity analyses – the effect of different components (including placebo) that characterize 
NBI, which is usually employed as the control condition in this field. We also restricted our 
literature search to include only RCTs designed to be blinded, and studies that strictly used 
CHR-P assessment instruments, to minimize selection biases. Therefore, to date, our study 
represents the most fine-grained analysis that has deconstructed the specific effect of 
preventive interventions for psychosis. 
Negative (non-significant) results are rarely published in psychiatric literature87, which is 
affected by excess of statistical significance88-92. In fact, interpreting negative findings is 
particularly challenging, because absence of evidence is not evidence of absence93. In 
particular, when large CIs are observed (as in Tables 2 and 3), some sizeable effects may 
still have been missed. Nevertheless, our work represents the most powered data synthesis 
in this field. For example, the meta-analysis by Stafford et al15 – on which current clinical 
guidelines are based – analyzed 11 studies, but one of them included an open-label trial 
(N=124)94 and another did not assess participants against standard CHR-P criteria (N=79)20, 
leaving nine studies (N=1,043) that are in common with the current NMA. Since that meta-
analysis, seven new trials involving 992 new CHR-P participants (an increase of more than 
50%) have been published, all of which reported non-significant effects41,72-74,76,78-80. Since 
our NMA included these new data, it is more powered than previous pairwise analyses.  
In the context of power considerations, indirect evidence, when combined with direct 
evidence through NMA, increases the power and precision of treatment effect estimates 
compared to pairwise analyses26. Furthermore, when we pooled different CBT protocols or 
antipsychotic molecules in the same node – thus increasing the statistical power – no 
significant results were still observed. Overall, the core result of our NMA is more congruent 
with the evidence emerging from the most recent trials, compared to previous evidence 
syntheses.  
The current lack of evidence to support specific preventive treatments is also consistent 
with the fact that the three largest interventional studies in this field have all produced 
negative findings95. Earlier studies that dominated the conclusions of some previous meta-
analyses (e.g., the omega-3 trial33) were likely false positives. There is also converging lack 
of significant benefits on other clinical outcomes besides transition to psychosis, such as 
attenuated symptom severity14,15,96, functioning10,14,18, depressive comorbidities15, distress14, 
and quality of life14,15.  
 14 
These findings, taken together, are particularly problematic given the conceptual 
concerns over the clinical validity and significance of the dichotomous concept of transition 
within the CHR-P paradigm97,98. More to the point, it is not clear whether the currently tested 
treatments are only delaying the onset of psychosis as opposed to altering the course of the 
disorder7. Long-term outcome trials are scarce and the results are conflicting. 
The additional caveat is that the exact mechanism of action of the tested preventive 
treatments is – at best – poorly defined, due to lack of an established and validated 
pathophysiological model underlying the onset of psychosis in CHR-P samples. A lack of 
mechanistic models forces researchers to proceed with empirical attempts that may 
eventually prove unsuccessful, as has ultimately been the case for omega-3 fatty acids76. 
However, as our ability to stratify CHR-P individuals into more homogenous subtypes 
improves, so may our success in testing specific treatments targeted to underlying biological 
and psychological mechanisms99.  
Our findings may have an impact on research and clinical practice. In times of scarce 
resources, our NMA can help to focus the next generation of research on the most promising 
interventions. Although our ranking analysis should be interpreted cautiously66,100 in the 
context of non-superiority of any intervention compared to any other, it suggests that CBT-F, 
which currently represents the most widely adopted intervention, may not be the best 
candidate (of relevance, the largest CBT-F trial to date provided non-significant results77). 
On the other hand, the apparent promising profile of integrated psychological approaches 
could be the target of future replications. 
Future research in this area will need to test novel interventions that may act on 
underlying psychological or neurobiological processes associated with the onset of 
psychosis. Although there are no clinically valid CHR-P biomarkers yet available101, several 
international consortia are ongoing (PRONIA102, NAPLS103, PSYSCAN104) with the aim of 
developing them. At the same time, it seems warranted to address the clinical 
heterogeneity1,6,49,105,106 that may prevent the discovery of reliable preventive treatments, and 
to improve the design of the next generation of trials. For example, it is apparent that 
unstructured recruitment processes and risk enrichment procedures in samples undergoing 
CHR-P assessment have a substantial role in determining the actual level of risk for 
psychosis in these individuals107-109, leading to underpowered and non-significant trials95. On 
a clinical side, individuals meeting CHR-P criteria may be informed that, at present, there is 
no evidence for specific treatments being more effective than any others, and current 
options should be carefully weighted on a personal basis depending on an individual’s 
needs.  
This study has some limitations. First, only 16 RCTs were included, reflecting the 
paucity of high-quality studies available in the CHR-P field. However, capitalizing on the 
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increased power and precision of NMA26, the Cochrane group has conducted such analysis 
in even smaller databases, including as few as three to seven studies110-113.  Furthermore, 
sufficient data were available for 6 and 12 month networks only, which precluded insight into 
whether treatments may have some effectiveness in the longer term. As a result of the 
sparse literature, many nodes were not well connected, with the corollary of limited ability to 
check for inconsistency, more imprecise estimates and wide 95% CIs. 
In addition, the quality of NMA rests on the quality of included studies, many of which 
were found to be at high or unclear risk of bias, with GRADE confidence estimates 
predominantly low or very low – suggesting that true effects may be substantially different 
from the estimates. This is particularly the case for trials including any psychological 
interventions. We addressed this issue through a strict and detailed assessment of biases 
and sensitivity analyses. Going forward, given that all comparisons in the NMA were 
downgraded due to study limitations (risk of bias) and imprecision, the addition of high-
quality studies with adequate sample sizes is needed to improve these confidence ratings.  
A final limitation is that, whilst dropout due to any cause was available from the majority 
of trials, this is a rather crude measure of treatment acceptability, and a more proximal 
index, such as specific adverse effects, may have revealed significant differences between 
treatments, in particular for trials of antipsychotic molecules. However, these outcomes are 
rarely reported in the CHR-P literature. 
In conclusion, there is no evidence at the moment to favor specific interventions for the 
prevention of psychosis. Further experimental research in this field is needed. 
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Figure 1   PRISMA flow chart of the study selection process. CHR-P - clinical high risk for psychosis, 
RCT - randomized controlled trial 
 
 
Records after duplicates removed 
(N=1,556) 
Records screened 
(N=1,556) 
Records excluded because not 
reporting interventional studies in 
CHR-P samples 
(N=1,507) 
Full-text articles 
assessed for eligibility 
(N=49) 
Full-text articles excluded  
(N=33) 
 
• Study protocol (N=5)  
• No control group (N=3) 
• Not blinded (N=1) 
• Not fully randomized (N=1) 
• Sample size <10 (N=2)  
• Not CHR-P sample (N=1) 
• Not RCT (N=8) 
• Longer follow-up/overlap (N=2) 
• No useable data (N=10)  
Studies included in 
systematic review 
(N=16) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(N=16) 
Records identified through 
database searching 
(N=1,697) 
Additional records identified 
through other sources 
(N=3) 
 24 
Table 1  Details of included studies  
 
Study Study arms (N) Network inclusion 
Treatment 
duration 
(months) 
Follow-
up time 
points 
(months) 
% 
male 
Mean 
age 
CHR-P 
criteria 
Study 
design Country 
% exposed to 
antipsychotics 
at baseline 
Addington et al30 CBT-F + NBI (27) NBI (24) 6, 12 6 6,12,18 71 20.5 SIPS SB-RCT Canada 0 
Amminger et al33 Omega-3 + NBI (41) NBI (40) 6, 12 3 6,12,84 33 16.4 PANSS DB-RCT Austria 0 
Bechdolf et al39 IPI (63) NBI (65) 6, 12 12 
6,12,18, 
24 63 26.0 ERIraos SB-RCT Germany 0 
Bechdolf et al72 
NBI + ARI (96) 
NBI (55) 
CBT-F + NBI (129) 
6, 12 12 6,12 66 24.4 SIPS + BS SB-RCT Germany 3.4 
Cadenhead et al73 Omega-3 + NBI (65) NBI (62) 6, 12 6 
6,12,18, 
24 NR NR SIPS DB-RCT US, Canada 0 
Kantrowitz et al74 D-serine + NBI (20) NBI (24) 6 4 4 66 19.4 SIPS DB-RCT US 11.4
 
McGlashan et al75 NBI + OLA (31) NBI (29) 6, 12 12 12, 24 65 17.7 SIPS DB-RCT US 10 
McGorry et al31 CBT-F + RIS + NBI (31) NBI (28) 6, 12 6 
6,12,36-
48 58 20.0 BPRS SB-RCT
 Australia 0 
McGorry et al76 Omega-3 + NBI (153) NBI (151) 6, 12 6 6,12 46 19.2 CAARMS DB-RCT Multi-national 0
 
Miklowitz et al41 FFT + NBI (66) NBI (63) 6 6 6 57 17.4 SIPS SB-RCT US 20.9 
Morrison et al36 CBT-F + NBI (37) NBI (23) 6, 12 6 6,12,36 67 22.0 CAARMS SB-RCT UK 0 
Morrison et al77 CBT-F + NBI (144) NBI (144) 6, 12 6 
6,12,18, 
24 63 20.7 CAARMS SB-RCT UK 0 
Stain et al78 CBT-F + NBI (30) NBI (27) 6, 12 6 6,12 40 16.3 CAARMS SB-RCT Australia 0 
van der Gaag et al37 
CBT-F + CBT-V + NBI 
(98) 
CBT-F + NBI (103) 
6, 12 6 6,12,18, 48 49 22.9 CAARMS SB-RCT 
The 
Netherlands 1.5 
Woods et al79 
Woods80 
NBI + ZIP (24) 
NBI (27) 6 6 6 64 22.3 SIPS DB-RCT US 0
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Study Study arms (N) Network inclusion 
Treatment 
duration 
(months) 
Follow-
up time 
points 
(months) 
% 
male 
Mean 
age 
CHR-P 
criteria 
Study 
design Country 
% exposed to 
antipsychotics 
at baseline 
Yung  et al81 
McGorry et al82 
CBT-F + NBI (44) 
CBT-F + RIS + NBI (43) 
NBI (28) 
6, 12 12 6,12 39 18.1 CAARMS SB-RCT Australia 0 
 
 
 
CBT - cognitive behavioural therapy, CBT-F  ̶  French & Morrison CBT protocol, NBI - needs-based interventions (including placebo), IPI - integrated 
psychological interventions, ARI - aripiprazole, OLA - olanzapine, RIS - risperidone, FFT - family-focused therapy, CBT-V - van der Gaag CBT protocol, ZIP 
- ziprasidone, SIPS - Structured Interview for Psychosis-risk Syndromes, PANSS - Positive and Negative Syndrome Scale, ERIraos - Early Recognition 
Inventory, BS - basic symptoms, BPRS - Brief Psychiatric Rating Scale, CAARMS - Comprehensive Assessment of At-Risk Mental States, SB-RCT - single-
blind randomized controlled trial, DB-RCT - double-blind randomized controlled trial, NR - not reported 
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Figure 2  Network plots of direct comparisons in the network meta-analysis for transition outcome at 6 (on the left) and 12 months (on the right). The width of 
the lines is proportional to the number of trials comparing each pair of treatments and the size of each node is proportional to the number of studies testing 
the specific treatment. The color of the lines represents the comparison-specific bias level for the blinding of outcome assessments in the majority of trials 
(black = low risk, dark grey = unclear risk, light grey = high risk). NBI - needs-based interventions (including placebo), IPI - integrated psychological 
interventions, FFT - family-focused therapy, Dser - D-serine, CBT - cognitive behavioural therapy, CBT-F - French & Morrison CBT protocol, CBT-V – van 
der Gaag CBT protocol, RIS - risperidone, Om3 - omega-3 fatty acids, ZIP - ziprasidone, OLA - olanzapine, ARI - aripiprazole  
CBT-F+CBT-V+NBI
CBT-F+NBI
CBT-F+RIS+NBIDser+NBI
FFT+NBI
IPI
NBI
NBI+ARI
NBI+OLA NBI+ZIP
Om3+NBI
CBT-F+CBT-V+NBI
CBT-F+NBI
CBT-F+RIS+NBI
IPI
NBI
NBI+ARI
NBI+OLA
Om3+NBI
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Table 2  Relative effect sizes for transition to psychosis and acceptability (dropout for any reason) at 6 months, odds ratios (95% CI) 
 
 
 
 
 
IPI - - - - - - - - - - 
0.39  
(0.00 to 31.26) FFT + NBI 
0.58  
(0.12 to 2.73) 
0.20  
(0.03 to 1.18) 
0.86  
(0.18 to 4.15) 
0.38  
(0.07 to 2.01) 
0.69  
(0.13 to 3.85) 
0.59  
(0.17 to 2.03) 
0.67  
(0.21 to 2.14) 
0.84  
(0.21 to 3.38) 
0.59  
(0.20 to 1.70) 
0.29  
(0.00 to 17.13) 
0.74  
(0.02 to 27.15) 
CBT-F + 
CBT-V +NBI 
0.34  
(0.05 to 2.09) 
1.48  
(0.32 to 6.85) 
0.65  
(0.12 to 3.56) 
1.19  
(0.21 to 6.82) 
1.01  
(0.28 to 3.65) 
1.15  
(0.41 to 3.21) 
1.43  
(0.37 to 5.60) 
1.01  
(0.33 to 3.08) 
0.22  
(0.00 to 12.43) 
0.57  
(0.02 to 19.56) 
0.77  
(0.03 to 17.86) OLA + NBI 
4.37  
(0.69 to 27.70) 
1.92  
(0.28 to 13.20) 
3.52  
(0.49 to 25.15) 
2.97  
(0.62 to 14.36) 
3.41  
(0.76 to 15.42) 
4.23  
(0.77 to 23.21) 
2.98  
(0.71 to 12.54) 
0.31  
(0.01 to 13.33) 
0.79  
(0.03 to 20.17) 
1.07  
(0.07 to 15.83) 
1.40  
(0.09 to 21.37) 
CBT-F + RIS 
+ NBI 
0.44  
(0.08 to 2.48) 
0.81  
(0.14 to 4.74) 
0.68  
(0.18 to 2.56) 
0.78  
(0.25 to 2.45) 
0.97  
(0.23 to 4.05) 
0.68  
(0.21 to 2.17) 
0.12  
(0.00 to 11.54) 
0.32  
(0.01 to 19.30) 
0.43  
(0.01 to 18.69) 
0.56  
(0.01 to 23.08) 
0.40  
(0.01 to 12.41) ZIP + NBI 
1.83  
(0.29 to 11.69) 
1.55  
(0.37 to 6.48) 
1.77  
(0.46 to 6.91) 
2.20  
(0.46 to 10.59) 
1.55  
(0.43 to 5.57) 
0.12  
(0.00 to 10.94) 
0.30  
(0.00 to 18.30) 
0.40  
(0.01 to 17.74) 
0.52  
(0.01 to 21.90) 
0.38  
(0.01 to 11.79) 
0.94  
(0.01 to 67.94) 
D-serine + 
NBI 
0.85  
(0.19 to 3.74) 
0.97  
(0.24 to 4.00) 
1.20  
(0.24 to 6.09) 
0.85  
(0.22 to 3.24) 
0.10  
(0.00 to 3.98) 
0.26  
(0.01 to 5.94) 
0.35  
(0.02 to 5.11) 
0.45  
(0.03 to 6.17) 
0.33  
(0.04 to 2.93) 
0.82  
(0.03 to 23.12) 
0.87  
(0.03 to 24.80) Om3 + NBI 
1.15  
(0.52 to 2.51) 
1.42  
(0.47 to 4.33) 
1.00  
(0.53 to 1.90) 
0.09  
(0.00 to 3.02) 
0.23  
(0.01 to 4.38) 
0.30  
(0.04 to 2.34) 
0.40  
(0.04 to 4.39) 
0.28  
(0.05 to 1.66) 
0.71  
(0.03 to 17.27) 
0.76  
(0.03 to 18.53) 
0.88  
(0.15 to 5.04) 
CBT-F + 
NBI 
1.24  
(0.50 to 3.06) 
0.87  
(0.55 to 1.37) 
0.07  
(0.00 to 3.19) 
0.18  
(0.01 to 4.89) 
0.24  
(0.02 to 3.56) 
0.31  
(0.02 to 5.26) 
0.22  
(0.02 to 2.38) 
0.56  
(0.02 to 18.82) 
0.59  
(0.02 to 20.18) 
0.68  
(0.07 to 6.84) 
0.78  
(0.13 to 4.64) ARI + NBI 
0.70  
(0.28 to 1.74) 
0.06  
(0.00 to 1.90) 
0.17  
(0.01 to 2.69) 
0.22  
(0.02 to 2.17) 
0.29  
(0.03 to 2.57) 
0.21  
(0.04 to 1.08) 
0.52  
(0.03 to 10.72) 
0.56  
(0.03 to 11.51) 
0.64  
(0.15 to 2.68) 
0.73  
(0.27 to 2.01) 
0.94  
(0.15 to 5.73) NBI 
 
 
Comparisons between treatments should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the 
row-defining treatment. Treatments are reported in descending order (from top left to bottom right) as per the cluster ranking for transition and acceptability. 
For transition, an OR less than 1 favors the column-defined treatment. For acceptability, an OR less than 1 favors the row-defined treatment. All 95% CIs 
include the null hypothesis OR=1. Dashes (-) indicate no available NMA estimate. CBT ̶ cognitive behavioural therapy, CBT-F - French & Morrison CBT 
protocol, CBT-V  ̶  van der Gaag CBT protocol, NBI - needs-based interventions, RIS - risperidone, FFT ̶  family-focused therapy, IPI - integrated 
Acceptability Transition  Comparison 
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psychological interventions, ARI  ̶  aripiprazole, OLA  ̶  olanzapine, ZIP  ̶  ziprasidone, Om3  ̶  omega-3 fatty acids 
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Table 3  Relative effect sizes for transition to psychosis and acceptability (dropout for any reason) at 12 months, odds ratios (95% CI) 
 
 
 
 
 
IPI 0.73  (0.15 to 3.48) 
1.49  
(0.34 to 6.54) 
1.43  
(0.35 to 5.89) 
1.72  
(0.55 to 5.43) 
1.37  
(0.41 to 4.54) 
1.68  
(0.57 to 4.91) 
2.72  
(0.75 to 9.83) 
0.26  
(0.01 to 12.94) OLA + NBI 
2.05  
(0.45 to 9.45) 
1.97  
(0.46 to 8.52) 
2.37  
(0.71 to 7.94) 
1.89  
(0.54 to 6.63) 
2.31  
(0.74 to 7.20) 
3.74  
(0.98 to 14.29) 
0.19  
(0.00 to 9.17) 
0.73  
(0.04 to 13.83) 
CBT-F + 
CBT-V +NBI 
0.96  
(0.26 to 3.51) 
1.15  
(0.45 to 2.93) 
0.92  
(0.30 to 2.86) 
1.12  
(0.41 to 3.11) 
1.82  
(0.57 to 5.84) 
0.09  
(0.00 to 3.23) 
0.35  
(0.03 to 4.35) 
0.48  
(0.05 to 5.03) 
CBT-F + RIS 
+ NBI 
1.20  
(0.49 to 2.95) 
0.96  
(0.33 to 2.74) 
1.17  
(0.47 to 2.93) 
1.89  
(0.62 to 5.76) 
0.07  
(0.00 to 2.06) 
0.26  
(0.03 to 2.60) 
0.35  
(0.06 to 2.20) 
0.74  
(0.17 to 3.22) CBT-F + NBI 
0.80  
(0.42 to 1.52) 
0.97  
(0.65 to 1.47) 
1.58  
(0.78 to 3.18) 
0.06  
(0.00 to 2.07) 
0.24  
(0.02 to 2.74) 
0.32  
(0.03 to 3.52) 
0.67  
(0.10 to 4.24) 
0.90  
(0.19 to 4.28) Om3 + NBI 
1.22  
(0.72 to 2.07) 
1.98  
(0.82 to 4.80) 
0.04  
(0.00 to 1.06) 
0.15  
(0.02 to 1.25) 
0.21  
(0.03 to 1.60) 
0.43  
(0.11 to 1.68) 
0.58  
(0.23 to 1.47) 
0.64  
(0.18 to 2.26) NBI 
1.62  
(0.80 to 3.29) 
0.03  
(0.00 to 1.13) 
0.11  
(0.01 to 1.60) 
0.15  
(0.01 to 1.72) 
0.31  
(0.04 to 2.47) 
0.42  
(0.08 to 2.14) 
0.46  
(0.06 to 3.72) 
0.72  
(0.14 to 3.78) ARI + NBI 
 
 
Comparisons between treatments should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the 
row-defining treatment. Treatments are reported in descending order (from top left to bottom right) as per the cluster ranking for transition and acceptability. 
For transition, an OR less than 1 favors the column-defined treatment. For acceptability, an OR less than 1 favors the row-defined treatment. All 95% CIs 
include the null hypothesis OR=1. CBT  ̶  cognitive behavioural therapy, CBT-F - French & Morrison CBT protocol, CBT-V  ̶  van der Gaag CBT protocol, 
NBI - needs-based interventions, RIS - risperidone, IPI - integrated psychological interventions, ARI  ̶  aripiprazole, OLA  ̶  olanzapine, Om3  ̶  omega-3 
fatty acids 
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